Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Alkermes Plc 1 BURLINGTON ROAD CONNAUGHT HOUSE DUBLIN L2 DUBLIN 4 IRL

www.alkermes.com P: 353-1772-8000

Description:

Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major therapeutic areas. Alkermes holds a diversified product portfolio and a promising pipeline of candidates targeting major central nervous system (CNS) disorders including schizophrenia, depression, addiction and multiple sclerosis. Alkermes derives revenues on net sales of its proprietary products: Vivitrol & Aristada, and manufacturing and/or royalty revenues on net sales of products commercialized by the company's partners. These include Risperdal Consta, Invega Sustenna/Xeplion, Invega Trinza/Trevicta, Ampyra/Fampyra and Bydureon. Interesting late-stage candidate in the company's pipeline include nemvaleukin alfa developed for treating advanced solid tumors. Its proprietary drugs are Vivitrol & Aristada.

Key Statistics

Overview:

Market Capitalization, $K 4,019,812
Enterprise Value, $K 3,853,072
Shares Outstanding, K 169,184
Annual Sales, $ 1,663 M
Annual Net Income, $ 355,760 K
Last Quarter Sales, $ 377,480 K
Last Quarter Net Income, $ 112,780 K
EBIT, $ 449,810 K
EBITDA, $ 524,740 K
60-Month Beta 0.55
% of Insider Shareholders 4.76%
% of Institutional Shareholders 95.21%
Float, K 161,131
% Float 95.24%
Short Volume Ratio 0.39

Growth:

1-Year Return -19.59%
3-Year Return 11.65%
5-Year Return -22.15%
5-Year Revenue Growth 52.01%
5-Year Earnings Growth 2,657.14%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.48 on 02/15/24
Latest Earnings Date 04/24/24 [--]
Earnings Per Share ttm 1.12
EPS Growth vs. Prev Qtr -32.00%
EPS Growth vs. Prev Year 1,800.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 142.87%
Most Recent Split 2-1 on 05/15/00

ALKS Ratios

Ratio
Price/Earnings ttm 21.44
Price/Earnings forward 10.67
Price/Earnings to Growth 0.66
Return-on-Equity % 16.10%
Return-on-Assets % 9.15%
Profit Margin % 21.39%
Debt/Equity 0.24
Price/Sales 2.44
Price/Cash Flow 10.47
Price/Book 3.30
Book Value/Share 7.21
Interest Coverage 19.30
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar